1. Pink Sheet
  2. >>Pathways & Standards
  3. >>Approval Standards

New Age Thinking: US FDA’s Temple Sees Third Era Of Drug Development

 
• By Michael McCaughan

Robert Temple, the FDA's voice of institutional memory, believes drug regulation has quietly entered a third era: the “Age of Individualization.” Unlike the prior eras of safety and efficacy, there is no milestone legislation to set the ground rules.

Dawn-new-era
Official notes significant under-appreciated changes in areas like the assessment of drug-drug interactions, metabolic response to therapeutics, and willingness for sub-population analyses. • Source: Shutterstock

The history of drug regulation by the US Food and Drug Administration is usually told as two discrete steps tied to landmark legislation: the 1938 FD&C Act that required premarket safety reviews for new drugs and the 1962 amendments that additionally required substantial evidence of efficacy prior to approval.

Center for Drug Evaluation and Research deputy director for clinical science Robert Temple, however, believes FDA drug regulation has now...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Approval Standards

More from Pathways & Standards

Slowdown: US FDA’s 2025 Novel Approvals Are On Below-Average Pace

 
• By Bridget Silverman

US FDA's 25 novel approvals in 2025 fell short of the agency's five-year average count, driven by a drop in drugs center approvals; 45 user fee goals remain in second half of year.

New US FDA Biologics License Pathway Could Be Missing Link To Reduce Animal Testing

 
• By Bridget Silverman

Akin to the 505(b)(2) NDA, a new biologic pathway could reduce the need for animal testing, FDA toxicologist says. Expanded use of generally accepted scientific knowledge (GASK), which few sponsors have attempted despite a 2023 draft guidance, would also help.

ANDA User Fees: Complex Generics, Transparency, Communications Are Early Negotiation Targets

 
• By Sue Sutter

Teva seeks a dedicated development program and first-cycle approval metrics for complex generics. Role of artificial intelligence in the generic drug review process is a talking point for both agency and industry at reauthorization kickoff meeting.